Clinical Trial Update: The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Growth Factor Signature as an intermediate biomarker for PI3K-pathway inhibitors in breast cancer; the MK-8669-050 trial is reported as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MK-8669-050

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED